



InformedDNA®

Genetics, Decoded.

Preimplantation Testing, Prenatal Cell-Free DNA Screening and Prenatal Diagnosis

Policy Number: GT03.1

Last Review Date: 10/01/2024
Previous Review Date: 04/01/2024

Table of Contents

Scope.....	3
State Biomarker Legislation.....	3
Guideline Coverage Criteria.....	3
Preimplantation Genetic Testing of Embryos.....	3
Prenatal Cell-Free DNA Screening.....	4
Prenatal Molecular Testing of a Fetus.....	4
Key Terms and Definitions.....	5
CPT® Codes.....	6
References.....	8
CPT Codes.....	8
Preimplantation Genetic Testing - Aneuploidy.....	8
Preimplantation Genetic Testing - Monogenic Disorders & Structural Rearrangements.....	11
Prenatal Cell-Free DNA Screening.....	13
Prenatal Molecular Testing of a Fetus.....	16
Change Summary.....	17

Scope

This evidence-based guideline addresses preimplantation genetic testing, non-invasive prenatal screening, and prenatal molecular testing of a fetus including chromosomal microarray analysis/genome wide copy number variant analysis. The criteria in this guideline do not apply to chromosome analysis or fluorescence in situ hybridization (FISH).

This guideline's coverage criteria delineate medically necessary clinical scenarios for molecular testing and may include specific situations when testing is considered never medically necessary. In general, molecular testing is considered never medically necessary when evidence demonstrating its ability to improve diagnosis, management, or clinical outcomes is lacking in peer-reviewed literature.

- Please refer to the Whole Exome Sequencing, Whole Genome Sequencing and Genome Wide Copy Number Variant Analysis coverage guideline for fetal sequencing criteria.

State Biomarker Legislation

Medical necessity determinations must also take into consideration controlling state coverage mandates that may supersede these guidelines when applicable. When state biomarker legislation requirements impact coverage decisions, this guideline will initially be applied to determine if criteria are met for approval. If an approval cannot be granted based on the criteria in this guideline, some or all of the following sources will be reviewed, as defined by applicable state legislation, to determine if test coverage is supported in a manner that is consistent with the state biomarker legislation requirements:

- Medicare National Coverage Determinations (NCDs)
- Medicare Local Coverage Determinations (LCDs)
- U.S. Food and Drug Administration (FDA) approved or cleared tests
- Tests indicated for an FDA-approved drug
- Nationally recognized clinical practice guidelines
- Consensus statements

Guideline Coverage Criteria

Preimplantation Genetic Testing of Embryos

Preimplantation genetic testing, including the embryo biopsy procedure if applicable, is medically necessary for the following indications:

Preimplantation Genetic Testing for Monogenic Disease (PGT-M)

- Both biologic parents are carriers of an autosomal recessive disorder

- One biologic parent is a known carrier of an autosomal dominant disorder or an X-linked disorder
- One biologic parent is a potential carrier, based on family history, of an autosomal dominant disorder or X-linked disorder and is requesting non-disclosure testing
- A previous pregnancy or child has been diagnosed with a genetic disorder and familial pathogenic/likely pathogenic (P/LP) variant(s) are known

Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)

- One biologic parent is a carrier of a chromosomal rearrangement

Preimplantation genetic testing is never medically necessary for any other indication, including but not limited to the following:

- human leukocyte antigen (HLA) typing of an embryo to identify a future suitable stem-cell tissue or organ transplantation donor
- nonmedical gender selection
- nonmedical traits
- preimplantation genetic testing for polygenic risk scores (PGT-P)
- preimplantation genetic testing for aneuploidy (PGT-A) by any testing methodology for any indication
- testing solely to determine if an embryo is a carrier of an autosomal recessive disorder
- testing for a multifactorial condition
- testing for variants of uncertain significance

Prenatal Cell-Free DNA Screening

Prenatal cell-free DNA screening (cfDNA) for trisomy 21, trisomy 18, trisomy 13 and/or sex chromosome aneuploidies is medically necessary for singleton or twin pregnancies.

Prenatal cell-free DNA screening is never medically necessary for the following indications:

- copy number variants (microdeletions or microduplications)
- autosomal trisomies other than 13, 18, and 21
- single gene conditions
- high-order multiple gestations (i.e., triplets or higher)
- twin zygoty
- multiple gestation pregnancies with fetal demise or vanishing twin
- miscarriage (including recurrent pregnancy loss) or fetal demise

Prenatal Molecular Testing of a Fetus

Prenatal molecular testing of a fetus (i.e., single gene or multi-gene testing) is medically necessary when the results of the genetic test will impact clinical decision-making and the requested method is scientifically valid for the suspected condition.

Chromosomal microarray/genome wide copy number variant analysis (81228, 81229, 81349) is medically necessary when invasive prenatal diagnostic testing is being performed.

Prenatal molecular testing in a fetus for familial variants of uncertain significance is never medically necessary.

Molecular analysis of intact fetal cells, i.e., fetal trophoblast(s) in a maternal sample, is never medically necessary.

Key Terms and Definitions

Aneuploidy is characterized by an extra or missing chromosome, as seen in conditions such as Down syndrome (trisomy 21), trisomy 13, or trisomy 18.

Autosomal dominant conditions are genetic disorders caused by one copy of an abnormal gene.

Autosomal recessive conditions are genetic disorders caused by two copies of an abnormal gene.

Chromosomes carry genetic material known as DNA; humans typically have 23 pairs of chromosomes.

Chromosomal microarray analysis is a genetic test that analyzes the entire genome for small deletions or duplications, known as copy number variants, in the DNA.

Chromosomal rearrangements are genetic alterations that involve the rearrangement of chromosome segments.

Copy number variants are small deletions or duplications in the DNA.

Deoxyribonucleic acid (DNA) is a molecule that contains the genetic instructions for all living organisms and plays a crucial role in the development and susceptibility to diseases.

Fetal trophoblasts are specialized cells that ultimately give rise to the placenta and can be found circulating in the maternal bloodstream.

Genes are segments of DNA that contain the instructions for specific traits, characteristics, or functions within an organism.

Genetic (molecular) testing examines a person's DNA or RNA to identify variations that can aid in the diagnosis of disease and/or provide valuable information about a person's risk of developing certain diseases.

Genome refers to an individual's entire set of genetic material (DNA).

Genome-wide copy number variant analysis is a genetic testing technique used to examine the entire genome to detect regions where there are abnormal gains or losses of DNA segments that can have significant implications for an individual's health.

Microdeletions refer to the loss of a small segment of DNA from one of the chromosomes.

Microduplications refer to the gain of a small segment of DNA from one of the chromosomes.

Monogenic disease is a genetic disorder caused by pathogenic variant(s) in a single gene.

Multifactorial conditions are health conditions that result from a combination of genetic and environmental factors, e.g. cancer, heart disease, and hypertension.

Multi-gene panels simultaneously analyze multiple genes associated with a particular condition or a group of related conditions.

Non-disclosure testing is a type of preimplantation genetic testing (PGT) that can be performed when an individual is at risk for a late-onset genetic disorder and does not want to know their own status but wants to prevent inheritance of the specific familial pathogenic variant.

Pathogenic/likely pathogenic variant(s) describe specific genetic changes that are known or highly likely to cause a particular genetic disorder, which can aid in diagnosis and/or guide treatment and management strategies.

Polygenic risk scores are numerical scores that estimate a person's risk for developing a particular trait or disease based on information from multiple genetic variants, each with small effects on the trait or disease in question.

Preimplantation genetic testing (PGT) is a genetic test used to screen embryos created during in vitro fertilization (IVF) for specific genetic disorders or chromosomal abnormalities.

Prenatal cell-free DNA screening (cfDNA) is a type of genetic test used during pregnancy to screen for certain chromosomal abnormalities or single gene disorders in the fetus by examining fetal DNA in the mother's bloodstream.

Sex chromosome aneuploidies are genetic disorders caused by an abnormal number of sex chromosomes; typically, either two X chromosomes (XX) or one X and one Y chromosome (XY) are present.

Structural rearrangements are genetic alterations that involve the rearrangement of chromosome segments.

Twin zygosity is the genetic similarity between twins, i.e., monozygotic (identical) or dizygotic (fraternal) twins.

X-linked disorder is a genetic disorder caused by a pathogenic variant in a gene located on the X chromosome.

Variants of uncertain significance (VUS) are genetic changes detected during genetic testing that cannot be definitively classified as benign (harmless) or pathogenic (disease-causing). Their impact on a person's health is not well understood based on scientific evidence available at the time of testing.

CPT[®] Codes

Medical necessity review of claims may include evaluation of the submitted codes. Laboratories must accurately represent their services using the most applicable and specific CPT code(s). Tier 1 molecular pathology procedure codes or Proprietary Laboratory Analyses (PLA) codes should be used when available for the specific test. Tier 2 molecular pathology procedure codes should only be used if the American Medical Association (AMA) has specifically assigned the performed test to such a code. Genomic sequencing procedures (GSP) codes (e.g., CPT codes 81410-81471) were developed by the AMA to represent multi-gene panels utilizing DNA or RNA analysis for specific clinical scenarios (e.g., carrier screening, tumor testing, etc.) and should be utilized when applicable.

Coding guidelines can be found in the AMA's CPT manual as well as the Centers for Medicare and Medicaid Services (CMS) National Correct Coding Initiative (NCCI) policy manuals. NCCI General Correct Coding Policy states that procedures should be reported with the most comprehensive CPT code describing the services performed and that the services described by a CPT code cannot be unbundled into multiple less specific codes. Additionally, GSP codes should be utilized when appropriate for the described test and should not be submitted along with other CPT codes that represent components of the GSP code.

Claims may not be approved if the submitted codes are not the most appropriate for the described procedure (i.e., as accurate and specific as available).

The following code(s) are medically necessary when coverage criteria are met. This list is not all inclusive.

Code	Full Description
81105	Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen

	CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P)
81106	Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M)
81107	Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S)
81108	Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q)
81109	Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant (eg, HPA-5a/b (K505E))
81110	Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-6a/b (R489Q)
81111	Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M)
81112	Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y)
81228	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis
81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis
81265	Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample])
81266	Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (eg, additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure)
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81442	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
0327U	Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized

	pregnancies, reported as selected antigen(s) detected or not detected
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative

The following code(s) are considered never medically necessary. This list is not all inclusive.

Code	Full Description
8142Z	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)
0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested
0489U	Obstetrics (single-gene noninvasive prenatal test), cell free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)

References

CPT Codes

AMA CPT® Professional 2024. American Medical Association

NCCI Policy Manual for Medicare Services. Available at:

<https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd>. Accessed quarterly.

NCCI Policy Manual for Medicaid Services. Available at:

<https://www.medicaid.gov/medicaid/program-integrity/national-correct-coding-initiative/medicaid-ncci-reference-documents/index.html>

Preimplantation Genetic Testing - Aneuploidy

Barad DH, Albertini DF, Molinari E, et al. IVF outcomes of embryos with abnormal PGT-A biopsy previously refused transfer: a prospective cohort study. *Hum Reprod*. 2022 May 30;37(6):1194-1206. doi: 10.1093/humrep/deac063. PMID: 35413106.

Braude P. The emperor still looks naked. *Reprod Biomed Online*. 2018 Aug;37(2):133-135. doi: 10.1016/j.rbmo.2018.06.018. PMID: 30075840.

Brezina PR, Anchan R, Kearns WG. Preimplantation genetic testing for aneuploidy: what technology should you use and what are the differences? *J Assist Reprod Genet*. 2016 Jul;33(7):823-32. doi: 10.1007/s10815-016-0740-2. Epub 2016 Jun 14. PMID: 27299602; PMCID: PMC4930789.

Capalbo A, Romanelli V, Patassini C, et al. Diagnostic efficacy of blastocoel fluid and spent media as sources of DNA for preimplantation genetic testing in standard clinical conditions. *Fertil Steril*. 2018 Oct;110(5):870-879.e5. doi: 10.1016/j.fertnstert.2018.05.031. Erratum in: *Fertil Steril*. 2019 Jan;111(1):194. PMID: 30316433.

Casper RF. PGT-A: Houston, we have a problem. *J Assist Reprod Genet*. 2023 Oct;40(10):2325-2332. doi: 10.1007/s10815-023-02913-w. Epub 2023 Aug 17. PMID: 37589859; PMCID: PMC10504172.

Cinnioglu C, Glessner H, Jordan A, et al. A systematic review of noninvasive preimplantation genetic testing for aneuploidy. *Fertil Steril*. 2023 Aug;120(2):235-239. doi: 10.1016/j.fertnstert.2023.06.013. Epub 2023 Jun 24. PMID: 37356468.

Coates A, Bankowski BJ, Kung A, et al. Differences in pregnancy outcomes in donor egg frozen embryo transfer (FET) cycles following preimplantation genetic screening (PGS): a single center retrospective study. *J Assist Reprod Genet*. 2017 Jan;34(1):71-78. doi: 10.1007/s10815-016-0832-z. Epub 2016 Nov 16. PMID: 27853913; PMCID: PMC5330984.

Dahdouh EM, Balayla J, Audibert F, et al. Technical Update: Preimplantation Genetic Diagnosis and Screening. *J Obstet Gynaecol Can*. 2015 May;37(5):451-63. doi: 10.1016/s1701-2163(15)30261-9. PMID: 26168107.

Debrock S, Melotte C, Spiessens C, et al. Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial. *Fertil Steril*. 2010 Feb;93(2):364-73. doi: 10.1016/j.fertnstert.2008.10.072. Epub 2009 Feb 26. PMID: 19249029.

Gleicher N, Barad DH, Ben-Rafael Z, et al. Commentary on two recently published formal guidelines on management of “mosaic” embryos after preimplantation genetic testing for aneuploidy (PGT-A). *Reprod Biol Endocrinol*. 2021 Feb 18;19(1):23. doi: 10.1186/s12958-021-00716-1. PMID: 33602283; PMCID: PMC7890905.

Gleicher N, Kushnir VA, Barad DH. How PGS/PGT-A laboratories succeeded in losing all credibility. *Reprod Biomed Online*. 2018 Aug;37(2):242-245. doi: 10.1016/j.rbmo.2018.06.019. PMID: 30075841.

Gleicher N, Orvieto R. Is the hypothesis of preimplantation genetic screening (PGS) still supportable? A review. *J Ovarian Res*. 2017 Mar 27;10(1):21. doi: 10.1186/s13048-017-0318-3. PMID: 28347334; PMCID: PMC5368937.

Gleicher N, Patrizio P, Brivanlou A. Preimplantation Genetic Testing for Aneuploidy – a Castle Built on Sand. *Trends Mol Med*. 2021 Jan 11:S1471-4914(20)30313-0. doi: 10.1016/j.molmed.2020.11.009. Epub ahead of print. PMID: 33446425.

Gleicher N, Vidali A, Braverman J, et al. International PGS Consortium Study Group. Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos. *Reprod Biol Endocrinol*. 2016 Sep 5;14(1):54. doi: 10.1186/s12958-016-0193-6. PMID: 27595768; PMCID: PMC5011996.

Grati FR, Gallazzi G, Branca L, et al. An evidence-based scoring system for prioritizing mosaic aneuploid embryos following preimplantation genetic screening. *Reprod Biomed Online*. 2018 Apr;36(4):442-449. doi: 10.1016/j.rbmo.2018.01.005. Epub 2018 Feb 9. PMID: 29433970.

Guzman L, Nuñez D, López R, Inoue N, Portella J, Vizcarra F, Noriega-Portella L, Noriega-Hoces L, Munné S. The number of biopsied trophectoderm cells may affect pregnancy outcomes. *J Assist Reprod Genet*. 2019 Jan;36(1):145-151. doi: 10.1007/s10815-018-1331-1. Epub 2018 Oct 17. PMID: 30328573; PMCID: PMC6338600.

Hardarson T, Hanson C, Lundin K, et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. *Hum Reprod*. 2008 Dec;23(12):2806-12. doi: 10.1093/humrep/den217. Epub 2008 Jun 25. PMID: 18583331.

Harper JC, Aittomäki K, Borry P, et al. Recent developments in genetics and medically assisted reproduction: from research to clinical applications. *Eur J Hum Genet*. 2018 Jan;26(1):12-33. doi: 10.1038/s41431-017-0016-z. Epub 2017 Dec 4. PMID: 29199274; PMCID: PMC5839000.

Kim TG, Neblett MF, Shandley LM, et al. National mosaic embryo transfer practices: a survey. *Am J Obstet Gynecol*. 2018 Dec;219(6):602.e1-602.e7. doi: 10.1016/j.ajog.2018.09.030. Epub 2018 Sep 29. PMID: 30278174.

Kushnir VA, Darmon SK, Barad DH, et al. Degree of mosaicism in trophectoderm does not predict pregnancy potential: a corrected analysis of pregnancy outcomes following transfer of mosaic embryos. *Reprod Biol Endocrinol*. 2018 Jan 26;16(1):6. doi: 10.1186/s12958-018-0322-5. PMID: 29373974; PMCID: PMC5787309.

Lee E, Illingworth P, Wilton L, et al. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. *Hum Reprod*. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28. PMID: 25432917.

Lee HL, McCulloh DH, Hodes-Wertz B, et al. In vitro fertilization with preimplantation genetic screening improves implantation and live birth in women age 40 through 43. *J Assist Reprod Genet*. 2015 Mar;32(3):435-44. doi: 10.1007/s10815-014-0417-7. Epub 2015 Jan 13. PMID: 25578536; PMCID: PMC4363234.

Li J, Liu Y, Qian Y, et al. Noninvasive preimplantation genetic testing in assisted reproductive technology: current state and future perspectives. *J Genet Genomics*. 2020 Dec 20;47(12):723-726. doi: 10.1016/j.jgg.2020.11.007. Epub 2021 Jan 26. PMID: 33674238.

Majumdar G, Majumdar A, Lall M, et al. Preimplantation genetic screening for all 24 chromosomes by microarray comparative genomic hybridization significantly increases implantation rates and clinical pregnancy rates in patients undergoing in vitro fertilization with poor prognosis. *J Hum Reprod Sci*. 2016 Apr-Jun;9(2):94-100. doi: 10.4103/0974-1208.183512. PMID: 27382234; PMCID: PMC4915293.

Mastenbroek S, Twisk M, van der Veen F, et al. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. *Hum Reprod Update*. 2011 Jul-Aug;17(4):454-66. doi: 10.1093/humupd/dmr003. Epub 2011 Apr 29. Erratum in: *Hum Reprod Update*. 2013 Mar-Apr;19(2):206. PMID: 21531751.

Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. *N Engl J Med*. 2007 Jul 5;357(1):9-17. doi: 10.1056/NEJMoa067744. Epub 2007 Jul 4. PMID: 17611204.

Maxwell SM, Colls P, Hodes-Wertz B, et al. Why do euploid embryos miscarry? A case-control study comparing the rate of aneuploidy within presumed euploid embryos that resulted in miscarriage or live birth using next-generation sequencing. *Fertil Steril*. 2016 Nov;106(6):1414-1419.e5. doi: 10.1016/j.fertnstert.2016.08.017. Epub 2016 Sep 28. PMID: 27692437.

Mejia R, Capper A, Summers K, et al. Cumulative live birth rate in women aged ≤37 years after in vitro fertilization with or without preimplantation genetic testing for aneuploidy: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System retrospective analysis. 2022 *Fertil Steril Repro*. Available at: <https://www.sciencedirect.com/science/article/pii/S2666334122000472>.

Meyer LR, Klipstein S, Hazlett WD, et al. A prospective randomized controlled trial of preimplantation genetic screening in the "good prognosis" patient. *Fertil Steril*. 2009 May;91(5):1731-8. doi: 10.1016/j.fertnstert.2008.02.162. Epub 2008 Sep 18. PMID: 18804207.

Munné S. Status of preimplantation genetic testing and embryo selection. *Reprod Biomed Online*. 2018 Oct;37(4):393-396. doi: 10.1016/j.rbmo.2018.08.001. Epub 2018 Aug 20. PMID: 30232021.

Munné S, Blazek J, Large M, et al. Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. *Fertil Steril*. 2017 Jul;108(1):62-71.e8. doi: 10.1016/j.fertnstert.2017.05.002. Epub 2017 Jun 1. PMID: 28579407.

Murugappan G, Ohno MS, Lathi RB. Cost-effectiveness analysis of preimplantation genetic screening and in vitro fertilization versus expectant management in patients with unexplained recurrent pregnancy loss. *Fertil Steril*. 2015 May;103(5):1215-20. doi: 10.1016/j.fertnstert.2015.02.012. Epub 2015 Mar 13. PMID: 25772770.

Orvieto R, Shuly Y, Brengauz M, Feldman B. Should pre-implantation genetic screening be implemented to routine clinical practice? *Gynecol Endocrinol*. 2016 Jun;32(6):506-8. doi: 10.3109/09513590.2016.1142962. Epub 2016 Feb 12. PMID: 26872945.

Pantou A, Mitrakos A, Kokkali G, et al. The impact of preimplantation genetic testing for aneuploidies (PGT-A) on clinical outcomes in high risk patients. *J Assist Reprod Genet.* 2022 Jun;39(6):1341-1349. doi: 10.1007/s10815-022-02461-9. Epub 2022 Mar 25. PMID: 35338417; PMCID: PMC9174385.

Practice Committee and Genetic Counseling Professional Group (GCPG) of the American Society for Reproductive Medicine. Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts: a committee opinion. *Fertil Steril.* 2020 Aug;114(2):246-254. doi: 10.1016/j.fertnstert.2020.05.014. PMID: 32741460.

Practice Committee of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. *Fertil Steril.* 2024 May 18:S0015-0282(24)00241-3. doi: 10.1016/j.fertnstert.2024.04.013. Epub ahead of print. PMID: 38762806.

Preimplantation Genetic Testing: ACOG Committee Opinion, Number 799. *Obstet Gynecol.* 2020 Mar;135(3):e133-e137. [Reaffirmed 2023] doi: 10.1097/AOG.0000000000003714. PMID: 32080053.

Quinn MM, Juarez-Hernandez F, Dunn M, et al. Decision-making surrounding the use of preimplantation genetic testing for aneuploidy reveals misunderstanding regarding its benefit. *J Assist Reprod Genet.* 2018 Dec;35(12):2155-2159. doi: 10.1007/s10815-018-1337-8. Epub 2018 Oct 18. PMID: 30334131; PMCID: PMC6289916.

Rosenwaks Z, Handyside AH, Fiorentino F, et al. The pros and cons of preimplantation genetic testing for aneuploidy: clinical and laboratory perspectives. *Fertil Steril.* 2018 Aug;110(3):353-361. doi: 10.1016/j.fertnstert.2018.06.002. PMID: 30098682.

Rubio C, Bellver J, Rodrigo L, et al. Preimplantation genetic screening using fluorescence in situ hybridization in patients with repetitive implantation failure and advanced maternal age: two randomized trials. *Fertil Steril.* 2013 Apr;99(5):1400-7. doi: 10.1016/j.fertnstert.2012.11.041. Epub 2012 Dec 20. PMID: 23260857.

Scott RT Jr, Upham KM, Forman EJ, et al. Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trial. *Fertil Steril.* 2013 Sep;100(3):624-30. doi: 10.1016/j.fertnstert.2013.04.039. Epub 2013 Jun 15. PMID: 23773313.

Scriven PN. Towards a better understanding of preimplantation genetic screening for aneuploidy: insights from a virtual trial for women under the age of 40 when transferring embryos one at a time. *Reprod Biol Endocrinol.* 2017 Jun 30;15(1):49. doi: 10.1186/s12958-017-0269-y. PMID: 28666459; PMCID: PMC5493873.

Sermon K. Novel technologies emerging for preimplantation genetic diagnosis and preimplantation genetic testing for aneuploidy. *Expert Rev Mol Diagn.* 2017 Jan;17(1):71-82. doi: 10.1080/14737159.2017.1262261. Epub 2016 Dec 1. PMID: 27855520.

Sordia-Hernandez LH, Morales-Martinez FA, González-Colmenero FD, et al. The Effects of Preimplantation Genetic Testing for Aneuploidy (PGT-A) on Patient-Important Outcomes in Embryo Transfer Cases: A Meta-Analysis. *J Reprod Infertil.* 2022 Oct-Dec;23(4):231-246. doi: 10.18502/jri.v23i4.10808. PMID: 36452195; PMCID: PMC9674466.

Staessen C, Platteau P, Van Assche E, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. *Hum Reprod.* 2004 Dec;19(12):2849-58. doi: 10.1093/humrep/deh536. Epub 2004 Oct 7. PMID: 15471934.

Tomic M, Vrtacnik Bokal E, Stimpfel M. Non-Invasive Preimplantation Genetic Testing for Aneuploidy and the Mystery of Genetic Material: A Review Article. *Int J Mol Sci.* 2022 Mar 25;23(7):3568. doi: 10.3390/ijms23073568. PMID: 35408927; PMCID: PMC8998436.

Verpoest W, Staessen C, M Bossuyt P, et al. Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. *Hum Reprod.* 2018 Sep 1;33(9):1767-1776. doi: 10.1093/humrep/dey262. PMID: 30085138.

Yakin K, Ata B, Ercelen N, et al. The effect of preimplantation genetic screening on the probability of live birth in young women with recurrent implantation failure; a nonrandomized parallel group trial. *Eur J Obstet Gynecol Reprod Biol.* 2008 Oct;140(2):224-9. doi: 10.1016/j.ejogrb.2008.05.005. Epub 2008 Jul 7. PMID: 18603347.

Yan J, Qin Y, Zhao H, et al. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy. *N Engl J Med.* 2021 Nov 25;385(22):2047-2058. doi: 10.1056/NEJMoa2103613. PMID: 34818479.

Preimplantation Genetic Testing - Monogenic Disorders & Structural Rearrangements

Abu-El-Haija A, Reddi HV, Wand H, et al. Electronic address: documents@acmg.net. The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2023 Mar 10:100803. doi: 10.1016/j.gim.2023.100803. Epub ahead of print. PMID: 36920474.

ACMG Board of Directors. Direct-to-consumer prenatal testing for multigenic or polygenic disorders: a position statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Nov;23(11):2027-2028. doi: 10.1038/s41436-021-01247-1. Epub 2021 Jun 28. Erratum in: *Genet Med.* 2021 Jul 23;: PMID: 34183790.

Bayefsky M. Who Should Regulate Preimplantation Genetic Diagnosis in the United States? *AMA J Ethics.* 2018 Dec 1;20(12):E1160-1167. doi: 10.1001/amajethics.2018.1160. PMID: 30585579.

Capalbo A, Romanelli V, Patassini C, et al. Diagnostic efficacy of blastocoel fluid and spent media as sources of DNA for preimplantation genetic testing in standard clinical conditions. *Fertil Steril.* 2018 Oct;110(5):870-879.e5. doi: 10.1016/j.fertnstert.2018.05.031. Erratum in: *Fertil Steril.* 2019 Jan;111(1):194. PMID: 30316433.

Chow JFC, Yeung WSB, Lee VCY, et al. Evaluation of preimplantation genetic testing for chromosomal structural rearrangement by a commonly used next generation sequencing workflow. *Eur J Obstet Gynecol Reprod Biol.* 2018 May;224:66-73. doi: 10.1016/j.ejogrb.2018.03.013. Epub 2018 Mar 9. PMID: 29547808.

Cinnioglu C, Glessner H, Jordan A, et al. A systematic review of noninvasive preimplantation genetic testing for aneuploidy. *Fertil Steril.* 2023 Aug;120(2):235-239. doi: 10.1016/j.fertnstert.2023.06.013. Epub 2023 Jun 24. PMID: 37356468.

Dahdouh EM, Balayla J, Audibert F, et al. Technical Update: Preimplantation Genetic Diagnosis and Screening. *J Obstet Gynaecol Can.* 2015 May;37(5):451-63. doi: 10.1016/s1701-2163(15)30261-9. PMID: 26168107.

Dungan JS, Klugman S, Darilek S, et al. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2022 Dec 13:S1098-3600(22)01004-8. doi: 10.1016/j.gim.2022.11.004. Epub ahead of print. PMID: 36524989.

Ethics Committee of the American Society for Reproductive Medicine. Use of preimplantation genetic testing for monogenic adult-onset conditions: an Ethics Committee opinion. *Fertil Steril.* 2024 Jun 28:S0015-0282(24)00514-4. doi: 10.1016/j.fertnstert.2024.05.165. Epub ahead of print. PMID: 38944787.

Forzano F, Antonova O, Clarke A, et al. Executive Committee of the European Society of Human Genetics; Public and Professional Policy Committee of the European Society of Human Genetics. The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice. *Eur J Hum Genet.* 2022 May;30(5):493-495. doi: 10.1038/s41431-021-01000-x. Epub 2021 Dec 17. Erratum in: *Eur J Hum Genet.* 2022 Mar 14;: PMID: 34916614; PMCID: PMC9090769.

Grebe TA, Khushf G, Greally JM, et al; ACMG Social, Ethical, and Legal Issues Committee. Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2024 Apr;26(4):101052. doi: 10.1016/j.gim.2023.101052. Epub 2024 Feb 23. PMID: 38393332.

Munné S. Status of preimplantation genetic testing and embryo selection. *Reprod Biomed Online*. 2018 Oct;37(4):393-396. doi: 10.1016/j.rbmo.2018.08.001. Epub 2018 Aug 20. PMID: 30232021.

Musunuru K, Hershberger RE, Day SM, et al.; American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. *Circ Genom Precis Med*. 2020 Aug;13(4):e000067. doi: 10.1161/HCG.0000000000000067. Epub 2020 Jul 23. PMID: 32698598.

Poulton A, Lewis S, Hui L, et al. Prenatal and preimplantation genetic diagnosis for single gene disorders: A population-based study from 1977 to 2016. *Prenat Diagn*. 2018 Nov;38(12):904-910. doi: 10.1002/pd.5352. Epub 2018 Sep 24. PMID: 30184264.

Practice Committee and Genetic Counseling Professional Group of the American Society for Reproductive Medicine, American Society for Reproductive Medicine, Washington, D.C.. Electronic address: asrm@asrm.org. Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion. *Fertil Steril*. 2023 Jul;120(1):61-71. doi: 10.1016/j.fertnstert.2023.03.003. Epub 2023 May 10. PMID: 37162432.

Practice Committee of Society for Assisted Reproductive Technology; Practice Committee of American Society for Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. *Fertil Steril*. 2008 Nov;90(5 Suppl):S136-43. doi: 10.1016/j.fertnstert.2008.08.062. PMID: 19007612.

Rechitsky S, Kuliev A. Preimplantation Genetic Testing (PGT) for non-traditional indications. *Reprod BioMed Online*. 2019;38:e3. doi: 10.1016/j.rbmo.2019.03.006.

Reddi HV, Wand H, Funke B, et al. Electronic address: documents@acmg.net. Laboratory perspectives in the development of polygenic risk scores for disease: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2023 May;25(5):100804. doi: 10.1016/j.gim.2023.100804. Epub 2023 Mar 27. PMID: 36971772.

Shear MA, Swanson K, Garg R, et al. A systematic review and meta-analysis of cell-free DNA testing for detection of fetal sex chromosome aneuploidy. *Prenat Diagn*. 2023 Feb;43(2):133-143. doi: 10.1002/pd.6298. Epub 2023 Jan 8. PMID: 36588186.

Siermann M, Tšuiiko O, Vermeesch JR, et al. A review of normative documents on preimplantation genetic testing: Recommendations for PGT-P. *Genet Med*. 2022 Mar 24:S1098-3600(22)00678-5. doi: 10.1016/j.gim.2022.03.001. Epub ahead of print. PMID: 35341652.

Simpson JL, Kuliev A, Rechitsky S. Overview of Preimplantation Genetic Diagnosis (PGD): Historical Perspective and Future Direction. *Methods Mol Biol*. 2019;1885:23-43. doi: 10.1007/978-1-4939-8889-1_2. PMID: 30506188.

Sullivan-Pyke C, Dokras A. Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis. *Obstet Gynecol Clin North Am*. 2018 Mar;45(1):113-125. doi: 10.1016/j.ogc.2017.10.009. PMID: 29428279.

Tomic M, Vrtacnik Bokal E, Stimpfel M. Non-Invasive Preimplantation Genetic Testing for Aneuploidy and the Mystery of Genetic Material: A Review Article. *Int J Mol Sci*. 2022 Mar 25;23(7):3568. doi: 10.3390/ijms23073568. PMID: 35408927; PMCID: PMC8998436.

Wilde AAM, Semsarian C, Márquez MF, et al; Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing

for cardiac diseases. *Europace*. 2022 Sep 1;24(8):1307-1367. doi: 10.1093/europace/euac030. Erratum in: *Europace*. 2022 Sep 1;24(8):1367. doi: 10.1093/europace/euac106. PMID: 35373836; PMCID: PMC9435643.

Prenatal Cell-Free DNA Screening

Acreman ML, Bussolaro S, Raymond YC, et al. The predictive value of prenatal cell-free DNA testing for rare autosomal trisomies: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2022 Aug 24:S0002-9378(22)00676-7. doi: 10.1016/j.ajog.2022.08.034. Epub ahead of print. PMID: 36027954.

Allen S, Young E, Bowns B. Noninvasive prenatal diagnosis for single gene disorders. *Curr Opin Obstet Gynecol*. 2017 Apr;29(2):73-79. doi: 10.1097/GCO.0000000000000347. PMID: 28134670.

American College of Obstetricians and Gynecologists Committee on Genetics; Hoskovec J, Russo M. Practice Advisory: Cell-free DNA to Screen for Single-Gene Disorders. 2019 Feb [reaffirmed 2021 Sept]. Available from: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2019/02/cell-free-dna-to-screen-for-single-gene-disorders>

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics, Society for Maternal-Fetal Medicine. Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231. *Obstet Gynecol*. 2021 Jun 1;137(6):e145-e162. doi: 10.1097/AOG.0000000000004397. PMID: 34011891.

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol*. 2020 Oct;136(4):e48-e69. doi: 10.1097/AOG.0000000000004084. PMID: 32804883.

Bender W, Dugoff L. Screening for Aneuploidy in Multiple Gestations: The Challenges and Options. *Obstet Gynecol Clin North Am*. 2018 Mar;45(1):41-53. doi: 10.1016/j.ogc.2017.10.004. PMID: 29428285.

Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn*. 2015 Aug;35(8):725-34. doi: 10.1002/pd.4608. Epub 2015 Jun 4. PMID: 25970088.

Beulen L, Faas BHW, Feenstra I, et al. Clinical utility of non-invasive prenatal testing in pregnancies with ultrasound anomalies. *Ultrasound Obstet Gynecol*. 2017 Jun;49(6):721-728. doi: 10.1002/uog.17228. PMID: 27515011; PMCID: PMC5488200.

Bianchi DW. Turner syndrome: New insights from prenatal genomics and transcriptomics. *Am J Med Genet C Semin Med Genet*. 2019 Jan 31. doi: 10.1002/ajmg.c.31675. Epub ahead of print. PMID: 30706680.

Bianchi DW, Chiu RWK. Sequencing of Circulating Cell-free DNA during Pregnancy. *N Engl J Med*. 2018 Aug 2;379(5):464-473. doi: 10.1056/NEJMra1705345. PMID: 30067923.

Bianchi DW, Parker RL, Wentworth J, et al. CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med*. 2014 Feb 27;370(9):799-808. doi: 10.1056/NEJMoa1311037. PMID: 24571752.

BlueCross BlueShield Association. Sequencing-based tests to determine fetal down syndrome (trisomy 21) from maternal plasma DNA. *Technol Eval Cent Assess Program Exec Summ*. 2013 Apr;27(10):1-6. PMID: 23866392.

Brison N, Van Den Bogaert K, Dehaspe L, et al. Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. *Genet Med*. 2017 Mar;19(3):306-313. doi: 10.1038/gim.2016.113. Epub 2016 Sep 1. PMID: 27584908.

Canick JA, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. *Prenat Diagn*. 2012 Aug;32(8):730-4. doi: 10.1002/pd.3892. Epub 2012 May 14. PMID: 22585317.

Chitty LS, Mason S, Barrett AN, et al. A. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. *Prenat Diagn*. 2015 Jul;35(7):656-62. doi: 10.1002/pd.4583. Epub 2015 May 26. PMID: 25728633; PMCID: PMC4657458.

Chu T, Yeniterzi S, Yatsenko SA, et al. High Levels of Sample-to-Sample Variation Confound Data Analysis for Non-Invasive Prenatal Screening of Fetal Microdeletions. *PLoS One*. 2016 Jun 1;11(6):e0153182. doi: 10.1371/journal.pone.0153182. Erratum in: *PLoS One*. 2016;11(9):e0163578. PMID: 27249650; PMCID: PMC4889033.

Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy. *Obstet Gynecol*. 2015 Sep;126(3):e31-e37. doi: 10.1097/AOG.0000000000001051. PMID: 26287791.

Dan S, Yuan Y, Wang Y, et al. Non-Invasive Prenatal Diagnosis of Lethal Skeletal Dysplasia by Targeted Capture Sequencing of Maternal Plasma. *PLoS One*. 2016 Jul 19;11(7):e0159355. doi: 10.1371/journal.pone.0159355. PMID: 27433940; PMCID: PMC4959253.

Dar P, Jacobsson B, Clifton R, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. *Am J Obstet Gynecol*. 2022 Jul;227(1):79.e1-79.e11. doi: 10.1016/j.ajog.2022.01.002. Epub 2022 Jan 13. PMID: 35033576.

Dar P, Jacobsson B, MacPherson C, et al. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. *Am J Obstet Gynecol*. 2022 Aug;227(2):259.e1-259.e14. doi: 10.1016/j.ajog.2022.01.019. Epub 2022 Jan 25. PMID: 35085538.

Devaney SA, Palomaki GE, Scott JA, et al. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. *JAMA*. 2011 Aug 10;306(6):627-36. doi: 10.1001/jama.2011.1114. PMID: 21828326; PMCID: PMC4526182.

Dondorp W, de Wert G, Bombard Y, et al; European Society of Human Genetics; American Society of Human Genetics. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. *Eur J Hum Genet*. 2015 Nov;23(11):1438-50. doi: 10.1038/ejhg.2015.57. Epub 2015 Mar 18. Erratum in: *Eur J Hum Genet*. 2015 Nov;23(11):1592. PMID: 25782669; PMCID: PMC4613463.

Dungan JS, Klugman S, Darilek S, et al. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2023 Feb;25(2):100336. doi: 10.1016/j.gim.2022.11.004. Epub 2022 Dec 16. PMID: 36524989.

Grömminger S, Yagmur E, Erkan S, et al. Fetal Aneuploidy Detection by Cell-Free DNA Sequencing for Multiple Pregnancies and Quality Issues with Vanishing Twins. *J Clin Med*. 2014 Jun 25;3(3):679-92. doi: 10.3390/jcm3030679. PMID: 26237471; PMCID: PMC4449645.

Horton RH, Wellesley DG. Extending non-invasive prenatal testing to non-invasive prenatal diagnosis. *Arch Dis Child Fetal Neonatal Ed*. 2019 Jan;104(1):F6-F7. doi: 10.1136/archdischild-2018-314845. Epub 2018 Jun 28. PMID: 29954879.

Huang X, Zheng J, Chen M, et al. Noninvasive prenatal testing of trisomies 21 and 18 by massively parallel sequencing of maternal plasma DNA in twin pregnancies. *Prenat Diagn*. 2014 Apr;34(4):335-40. doi: 10.1002/pd.4303. Epub 2014 Feb 3. PMID: 24357023.

Jenkins LA, Deans ZC, Lewis C, et al. Delivering an accredited non-invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice. *Prenat Diagn*. 2018 Jan;38(1):44-51. doi: 10.1002/pd.5197. PMID: 29266293.

Lau TK, Cheung SW, Lo PS, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. *Ultrasound Obstet Gynecol*. 2014 Mar;43(3):254-64. doi: 10.1002/uog.13277. Epub 2014 Feb 10. PMID: 24339153.

Lefkowitz RB, Tynan JA, Liu T, et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. *Am J Obstet Gynecol*. 2016 Aug;215(2):227.e1-227.e16. doi: 10.1016/j.ajog.2016.02.030. Epub 2016 Feb 17. PMID: 26899906.

Mather CA, Qi Z, Wiita AP. False positive cell free DNA screening for microdeletions due to non-pathogenic copy number variants. *Prenat Diagn*. 2016 Jun;36(6):584-6. doi: 10.1002/pd.4823. Epub 2016 May 12. PMID: 27061292.

Nicolaides KH, Syngelaki A, Gil M, et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. *Prenat Diagn*. 2013 Jun;33(6):575-9. doi: 10.1002/pd.4103. Epub 2013 Apr 24. PMID: 23613152.

Palomaki GE, Chiu RWK, Pertile MD, et al. International Society for Prenatal Diagnosis Position Statement: cell free (cf)DNA screening for Down syndrome in multiple pregnancies. *Prenat Diagn*. 2021 Sep;41(10):1222-1232. doi: 10.1002/pd.5832. Epub 2020 Nov 15. PMID: 33016373.

Petersen AK, Cheung SW, Smith JL, et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. *Am J Obstet Gynecol*. 2017 Dec;217(6):691.e1-691.e6. doi: 10.1016/j.ajog.2017.10.005. Epub 2017 Oct 13. PMID: 29032050.

Ravi H, McNeill G, Goel S, et al. Validation of a SNP-based non-invasive prenatal test to detect the fetal 22q11.2 deletion in maternal plasma samples. *PLoS One*. 2018 Feb 23;13(2):e0193476. doi: 10.1371/journal.pone.0193476. PMID: 29474437; PMCID: PMC5825123.

Rego de Sousa MJ, Albuquerque M, Ribeiro R, et al. Evaluation of Noninvasive Prenatal Testing (NIPT) guidelines using the AGREE II instrument. *J Matern Fetal Neonatal Med*. 2020 Feb;33(3):455-463. doi: 10.1080/14767058.2018.1494716. Epub 2018 Sep 9. PMID: 30205421.

Rose NC, Barrie ES, Malinowski J, et al. Systematic evidence-based review: The application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies. *Genet Med*. 2022 May 10:S1098-3600(22)00714-6. doi: 10.1016/j.gim.2022.03.019. Epub ahead of print. PMID: 35608568.

Samango-Sprouse C, Banjevic M, Ryan A, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. *Prenat Diagn*. 2013 Jul;33(7):643-9. doi: 10.1002/pd.4159. Epub 2013 Jun 20. PMID: 23712453; PMCID: PMC3764608.

Scott F, Bonifacio M, Sandow R, et al. Rare autosomal trisomies: Important and not so rare. *Prenat Diagn*. 2018 Sep;38(10):765-771. doi: 10.1002/pd.5325. Epub 2018 Jul 17. PMID: 29956348.

Shear MA, Swanson K, Garg R, et al. A systematic review and meta-analysis of cell-free DNA testing for detection of fetal sex chromosome aneuploidy. *Prenat Diagn*. 2023 Feb;43(2):133-143. doi: 10.1002/pd.6298. Epub 2023 Jan 8. PMID: 36588186.

Srebniak MI, Vogel I, Van Opstal D. Is carriership of a balanced translocation or inversion an indication for non-invasive prenatal testing? *Expert Rev Mol Diagn*. 2018 Jun;18(6):477-479. doi: 10.1080/14737159.2018.1468255. Epub 2018 Apr 26. PMID: 29676188.

Verhoef TI, Hill M, Drury S, et al. Non-invasive prenatal diagnosis (NIPD) for single gene disorders: cost analysis of NIPD and invasive testing pathways. *Prenat Diagn*. 2016 Jul;36(7):636-42. doi: 10.1002/pd.4832. Epub 2016 May 22. PMID: 27107169; PMCID: PMC6680142.

Wapner RJ, Babiarz JE, Levy B, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. *Am J Obstet Gynecol*. 2015 Mar;212(3):332.e1-9. doi: 10.1016/j.ajog.2014.11.041. Epub 2014 Dec 2. PMID: 25479548.

Yaron Y. The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. *Prenat Diagn*. 2016 May;36(5):391-6. doi: 10.1002/pd.4804. Epub 2016 Apr 2. PMID: 26941176.

Zhang J, Li J, Saucier JB, et al. Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. *Nat Med.* 2019 Mar;25(3):439-447. doi: 10.1038/s41591-018-0334-x. Epub 2019 Jan 28. Erratum in: *Nat Med.* 2019 Feb 20;; PMID: 30692697.

Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. *Clin Chem.* 2015 Apr;61(4):608-16. doi: 10.1373/clinchem.2014.233312. Epub 2015 Feb 20. PMID: 25710461.

Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. *Prenat Diagn.* 2012 Dec;32(13):1233-41. doi: 10.1002/pd.3993. Epub 2012 Oct 30. PMID: 23108718; PMCID: PMC3548605.

Prenatal Molecular Testing of a Fetus

Armour CM, Dougan SD, Brock JA, et al.; On-Behalf-Of the Canadian College of Medical Geneticists. Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada. *J Med Genet.* 2018 Apr;55(4):215-221. doi: 10.1136/jmedgenet-2017-105013. Epub 2018 Mar 1. PMID: 29496978; PMCID: PMC5869456.

Chaubey A, Shenoy S, Mathur A, et al. Low-Pass Genome Sequencing: Validation and Diagnostic Utility from 409 Clinical Cases of Low-Pass Genome Sequencing for the Detection of Copy Number Variants to Replace Constitutional Microarray. *J Mol Diagn.* 2020 Jun;22(6):823-840. PMID: 32344035.

Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. *Obstet Gynecol.* 2016 Dec;128(6):e262-e268. [Reaffirmed 2023] doi: 10.1097/AOG.0000000000001817. PMID: 27875474.

Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. *Obstet Gynecol.* 2016 May;127(5):e108-e122. doi: 10.1097/AOG.0000000000001405. PMID: 26938573.

Robson SC, Chitty LS, Morris S, et al. Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies: a multicentre cohort study with cost analysis and assessment of patient, health professional and commissioner preferences for array comparative genomic hybridisation. Southampton (UK): NIHR Journals Library; 2017 Feb. PMID: 28182369.

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dugoff L, Norton ME, Kuller JA. The use of chromosomal microarray for prenatal diagnosis. *Am J Obstet Gynecol.* 2016 Oct;215(4):B2-9. doi: 10.1016/j.ajog.2016.07.016. Epub 2016 Jul 15. Erratum in: *Am J Obstet Gynecol.* 2017 Feb;216(2):180. PMID: 27427470.

Change Summary

Version	Review Date	Effective Date	Summary of Revisions
Created	CSC: 8/11/2022 PAB: 9/12/2022	November 2022	Not applicable
v1.2023	COOC: 2/15/2023 PAB: 3/16/2023	April 1, 2023	Semi-annual review. No criteria changes.
v2.2023	COOC: 8/16/2023 PAB: 9/25/2023	October 1, 2023	Semi-annual review. Criteria were reformatted with no impact on coverage.

v1.2024	COOC: 2/14/2024 PAB: 3/25/2024	April 1, 2024	Semi-annual review. No criteria changes. Clarifications were made to the scope and CPT code section with no impact on coverage except 0449U was removed from the NMN CPT code table. References were updated.
v2.2024	COOC: 08/19/2024 PAB: 09/20/2024	October 1, 2024	Semi-annual review. No criteria changes. CPT codes and references were updated.